Table 4.
Representative enriched KEGG Pathways
| ID | Term | P-value |
|---|---|---|
| hsa04010 | MAPK signaling pathway | 3.16E-11 |
| hsa04012 | ErbB signaling pathway | 6.97E-9 |
| hhsa04660 | T cell receptor signaling pathway | 4.33E-6 |
| hsa04310 | Wnt signaling pathway | 9.34E-6 |
| hsa04664 | Fc epsilon RI signaling pathway | 2.44E-4 |
| hsa04910 | Insulin signaling pathway | 0.006 |
| hsa05220 | Chronic myeloid leukemia | 1.57E-9 |
| hsa05212 | Pancreatic cancer | 8.44E-7 |
| hsa05215 | Prostate cancer | 1.59E-5 |
| hsa05210 | Colorectal cancer | 3.95E-5 |
| hsa05222 | Small cell lung cancer | 5.57E-5 |
Representative enriched KEGG Pathways on the subnetwork affected by Avandamet.